Aa
regarding latest HCV drugs.
Which is the latest oral drug available for treatment of hep.c.
I do not know a great deal about Genotype 3 and the treatmen of Genotype 3, but I did find a good article on Genotype 3 treatment.It is worth copying the link and reading the entire article.
I copied and pasted 2 paragraphs from a recent article on treating Genotype 3.
"Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies" 29 DEC 2011
"Genotype 3 is a common type of HCV infection, and standard therapy using pegylated interferon (PEG-IFN) and ribavirin (RBV) is quite effective in these patients. While a short course of 16 weeks may result in comparable end of therapy responses, relapse rates are often high. A 24-week course is therefore preferable, and is expected to result in sustained virological response (SVR) rates of more than 70%. The 24-week course is especially recommended in the presence of steatosis (often associated with Genotype 3 infection), fibrosis stage two or more, high BMI and high viral load. In patients who do not achieve a rapid viral response (RVR) with combination therapy, an extended course up to 48 weeks should be considered. "
"According to the recent AASLD guidelines [15], PEG-IFN -2b (1.5 μg/kg/week) plus RBV (800–1400 mg/day) or PEG-IFN -2a (180 μg/week) plus RBV (800 mg/day) for 24 weeks are the established SOC regimens for patients with chronic hepatitis C genotype 2 or 3. However, optimal administration of PEG-IFN/RBV, in particular, the duration and the dosage have still not been clearly established in relation to outcome in rapid and slow responders. Based on the concept of ‘response guided treatment,’a recent meta-analysis evaluated the issue of decreasing the duration of treatment to improve tolerance and cost effectiveness, and most importantly to decrease viral resistance to the standard bitherapy [16]. Treatment with PEG-IFN and weight-based RBV for 16 weeks in patients a with rapid virological response (RVR) resulted in an SVR of 76.3% and 86.4% with 24 weeks of treatment, unlike genotype 2 which was 83.8% and 89.3% respectively. This was because of increased relapse rates in patients with genotype 3. "
http://hepatitiscnewdrugs.blogspot.com/2012/01/treatment-of-patients-with-genotype-3.html
I hope this helps a little. I wish I knew more about Genotype 3 and its treatment, but I don't, so I will give you the link. As far as I know the Interferon and Ribavirin are the two drugs used to treat Genotype 3. As far as I know, the new protease inhibitors are not generally being used to treat Genotype 3.
Hopefully someone who knows more about Genotype 3 and its treatment will respond.
I wish you and your daughter the best and hope she can clear the virus.
I copied and pasted 2 paragraphs from a recent article on treating Genotype 3.
"Treatment of patients with genotype 3 chronic hepatitis C- current and future therapies" 29 DEC 2011
"Genotype 3 is a common type of HCV infection, and standard therapy using pegylated interferon (PEG-IFN) and ribavirin (RBV) is quite effective in these patients. While a short course of 16 weeks may result in comparable end of therapy responses, relapse rates are often high. A 24-week course is therefore preferable, and is expected to result in sustained virological response (SVR) rates of more than 70%. The 24-week course is especially recommended in the presence of steatosis (often associated with Genotype 3 infection), fibrosis stage two or more, high BMI and high viral load. In patients who do not achieve a rapid viral response (RVR) with combination therapy, an extended course up to 48 weeks should be considered. "
"According to the recent AASLD guidelines [15], PEG-IFN -2b (1.5 μg/kg/week) plus RBV (800–1400 mg/day) or PEG-IFN -2a (180 μg/week) plus RBV (800 mg/day) for 24 weeks are the established SOC regimens for patients with chronic hepatitis C genotype 2 or 3. However, optimal administration of PEG-IFN/RBV, in particular, the duration and the dosage have still not been clearly established in relation to outcome in rapid and slow responders. Based on the concept of ‘response guided treatment,’a recent meta-analysis evaluated the issue of decreasing the duration of treatment to improve tolerance and cost effectiveness, and most importantly to decrease viral resistance to the standard bitherapy [16]. Treatment with PEG-IFN and weight-based RBV for 16 weeks in patients a with rapid virological response (RVR) resulted in an SVR of 76.3% and 86.4% with 24 weeks of treatment, unlike genotype 2 which was 83.8% and 89.3% respectively. This was because of increased relapse rates in patients with genotype 3. "
http://hepatitiscnewdrugs.blogspot.com/2012/01/treatment-of-patients-with-genotype-3.html
I hope this helps a little. I wish I knew more about Genotype 3 and its treatment, but I don't, so I will give you the link. As far as I know the Interferon and Ribavirin are the two drugs used to treat Genotype 3. As far as I know, the new protease inhibitors are not generally being used to treat Genotype 3.
Hopefully someone who knows more about Genotype 3 and its treatment will respond.
I wish you and your daughter the best and hope she can clear the virus.
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
